Log in to search using one of your social media accounts:

 

ESC: Unexpected Results with Direct Thrombin Inhibitor in PCI (CME/CE)
(MedPage Today) -- Bivalirudin doesn't reduce bleeding in registry-based VALIDATE-SWEDEHEART (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 27, 2017 Category: Cardiology Source Type: news

No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news

BRAVO 3: Still No Place for Bivalirudin in TAVR
(MedPage Today) -- No major interactions with Afib status or valve type in trials (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 14, 2017 Category: Cardiology Source Type: news

BRAVO 3 TAVR and AF: Stroke Risk, Discharge Meds Differ BRAVO 3 TAVR and AF: Stroke Risk, Discharge Meds Differ
In the BRAVO-3 trial of patients who had transfemoral TAVR with procedural bivalirudin or heparin, patients with new-onset AF had a much greater stroke risk; there was also an"incredible" variation in discharge meds.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 12, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Analysis looks at role type of valve plays in patient outcomes post-TAVR
(Society for Cardiovascular Angiography and Interventions) Results from 'Impact of valve design and bivalirudin vs. unfractionated heparin for anticoagulation in transcatheter aortic valve replacement: Results from the BRAVO-3 trial' were presented today as a late-breaking clinical trial at the Society for CardiovascularAngiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 12, 2017 Category: International Medicine & Public Health Source Type: news

Analysis shows increased risk of early stroke with new-onset atrial fibrillation post-TAVR
(Society for Cardiovascular Angiography and Interventions) Results from 'Effect of bivalirudin versus unfractionated heparin in patients with baseline or new-onset atrial fibrillation in transcatheter aortic valve replacement: From the BRAVO-3 randomized trial' were presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 11, 2017 Category: International Medicine & Public Health Source Type: news

Bivalirudin in Briefer PCI May Boost Stent Thrombosis Risk Bivalirudin in Briefer PCI May Boost Stent Thrombosis Risk
Shorter percutaneous coronary intervention (PCI) procedures are associated with an increased risk of acute stent thrombosis (AST) in patients treated with bivalirudin, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 7, 2017 Category: Consumer Health News Tags: Emergency Medicine News Source Type: news

Bivalirudin Ill-Suited for Speedy Stenting?
(MedPage Today) -- More stent thrombosis seen with fast-acting drug in brief procedures (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 2, 2017 Category: Cardiology Source Type: news

Bivalirudin (Angiomax) (Bivalirudin Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 23, 2017 Category: Drugs & Pharmacology Source Type: news

Bivalirudin (Angiomax) (Bivalirudin Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 23, 2017 Category: Drugs & Pharmacology Source Type: news

Intracoronary Bivalirudin in STEMI Patients Treated With PCI Intracoronary Bivalirudin in STEMI Patients Treated With PCI
This report describes a novel off-label protocol for bivalirudin administration in patients with STEMI undergoing PCI. What advantages does it offer over the standard intravenous route?American Journal of Cardiovascular Drugs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 3, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Angiomax Edges Heparin on Real-World Bleeding Complications
(MedPage Today) -- Glycoprotein IIb/IIIa inhibitors a factor, according to registry findings (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 12, 2016 Category: Cardiology Source Type: news

Cath Lab Recap: More CRT Software; Bivalirudin Patent Kerfuffle
(MedPage Today) -- Interventional cardiology news to note (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - July 14, 2016 Category: Urology & Nephrology Source Type: news

Angiomax (Bivalirudin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 13, 2016 Category: Drugs & Pharmacology Source Type: news

Federal Circuit Rules for The Medicines Company in Angiomax(R) (bivalirudin) Patent Litigation
PARSIPPANY, N.J.--(Healthcare Sales & Marketing Network)--The Medicines Company announced that the U.S. Court of Appeals for the Federal Circuit Court, in an en banc review, unanimously affirmed the earlier district court ruling in The Medicines Company v.... Biopharmaceuticals, Cardiology, LitigationThe Medicines Company, Angiomax, bivalirudin, Hospira (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2016 Category: Pharmaceuticals Source Type: news

Longer Infusion Gives Bivalirudin the Upper Hand in PCI
(MedPage Today) -- Acute stent thrombosis, major bleeding rates favorable in meta-analysis (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 15, 2016 Category: Cardiology Source Type: news

PCI Quality Initiative Cuts Bivalirudin Use, Cost, and BleedingPCI Quality Initiative Cuts Bivalirudin Use, Cost, and Bleeding
"Perhaps more important, by using a risk-directed approach to coronary intervention, we were able to cut our bleeding rate nearly in half," the study author stressed. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 8, 2016 Category: Cardiology Tags: Cardiology News Source Type: news

SCAI: No Early Sex Differences For TAVR
(MedPage Today) -- Bravo 3 substudy suggests benefit for women on bivalirudin, though (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 6, 2016 Category: Cardiology Source Type: news

Morphine at Acute MI May Blunt Short-Term Antiplatelet ResponseMorphine at Acute MI May Blunt Short-Term Antiplatelet Response
"Once morphine is given, we may consider giving other IV agents that bypass the gastric emptying, such as GP IIb/IIIa inhibitors or bivalirudin," propose investigators after their prospective study. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 3, 2016 Category: Cardiology Tags: Cardiology News Source Type: news

TCT: Structural Heart Disease and PFO Closure TrialsTCT: Structural Heart Disease and PFO Closure Trials
Drs Harrington and Bhatt discuss whether transcatheter aortic valve therapy is evolving naturally or moving beyond the evidence, bivalirudin in TAVR, and PFO closure for stroke prevention. theheart.org on Medscape (Source: theHeart.org)
Source: theHeart.org - October 19, 2015 Category: Cardiology Tags: Cardiology Commentary Source Type: news

TCT: Anticoagulants Equal in Aortic Valve Replacement
(MedPage Today) -- Bivalirudin, unfractionated heparin similar for bleeding and net outcomes in BRAVO 3 (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 16, 2015 Category: Cardiology Source Type: news

BRAVO 3: Bivalirudin No Better Than Heparin in TAVRBRAVO 3: Bivalirudin No Better Than Heparin in TAVR
In BRAVO 3, the use of bivalirudin yielded no benefit over unfractionated heparin, which experts say should limit its use to a small segment of patients, such as those with heparin-induced thrombocytopenia. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 15, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

ESC Interventional Cardiology HighlightsESC Interventional Cardiology Highlights
Drs Fox and Stone review late-breaking data on bioresorbable stents, FFRCT, and bivalirudin from the European Society of Cardiology Congress. theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 11, 2015 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Sep 4 Cardiology NewsSep 4 Cardiology News
Dr John Mandrola discusses studies from ESC, including CT-FFR, post-PCI bivalirudin, ezetimibe in diabetes, high-sensitivity troponin, resistant HTN, leadless pacing, and afternoon naps. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 4, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

Expensive blood thinner no more effective than cheaper drug
Stephen FellerGREAT NECK, N.Y., Sept. 2 (UPI) -- Conflicting studies on the blood-thinning drugs heparin and bivalirudin show them to have no clear benefit over one another aside from one being more expensive. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 2, 2015 Category: Consumer Health News Source Type: news

MATRIX: Is There A Benefit From Longer Bivalirudin Infusion?MATRIX: Is There A Benefit From Longer Bivalirudin Infusion?
Prolonging the infusion of bivalirudin for several hours after the completion of PCI did not reduce the composite outcome of ischemic and bleeding end points, but a nonrandomized exploratory analysis suggests the high-dose prolonged infusion may show better results. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 1, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

ESC: Extending Angiomax after PCI Unhelpful (CME/CE)
(MedPage Today) -- Bleeding and stent thrombosis not influenced by continuation of treatment (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 1, 2015 Category: Cardiology Source Type: news

Court Rules Patents for Medicines Co.'s Anticlotting Drug Invalid
Medicines Co. said Thursday that a federal circuit court has ruled against the company in its patent suit against Hospira Inc., deeming the patents for its anticlotting drug Angiomax invalid. (Source: WSJ.com: Health)
Source: WSJ.com: Health - July 2, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news

Disparate Narratives on Bivalirudin PersistDisparate Narratives on Bivalirudin Persist
Whether bivalirudin is associated with lower bleeding and mortality in primary PCI vs heparin and a similar level of glycoprotein IIb/IIIa remains the topic of debate after MATRIX and BRIGHT. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 11, 2015 Category: Cardiology Tags: Cardiology Article Source Type: news

Bivalirudin in Primary PCI: Squaring the DataBivalirudin in Primary PCI: Squaring the Data
With multiple trials using different drug regimens and dosing, Drs Steg and Storey try to make sense of the findings on bivalirudin in primary PCI. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 10, 2015 Category: Cardiology Tags: Cardiology Commentary Source Type: news

BRIGHT: Bivalirudin Bests Heparin, but Dose May MatterBRIGHT: Bivalirudin Bests Heparin, but Dose May Matter
Debate over bivalirudin vs heparin continues with the print publication of BRIGHT. But experts shed some light on why results were better for bivalirudin here than in the recent HEAT-PPC trial. Heartwire from Medscape (Source: theHeart.org)
Source: theHeart.org - April 13, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

Sun Pharma settles Angiomax litigation with The Medicines Company
Under the terms of the agreement, the company's subsidiary is entitled to launch its version of generic Angiomax in the US on June 30, 2019. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 1, 2015 Category: Pharmaceuticals Source Type: news

MATRIX: Bivalirudin Reduced Mortality vs UFH in ACS SettingMATRIX: Bivalirudin Reduced Mortality vs UFH in ACS Setting
On its primary MACE end point, the MATRIX study missed in showing the superiority of bivalirudin over unfractionated heparin in ACS patients undergoing PCI, but mortality and bleeding advantages were observed. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 20, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

ACC: MATRIX Scores for Transradial
(MedPage Today) -- But Angiomax again comes up short against unfractioned heparin. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 18, 2015 Category: Cardiology Source Type: news

Findings from the BRIGHT trial published in JAMA
(Cardiovascular Research Foundation) Data from the BRIGHT trial published today in the Journal of the American Medical Association demonstrated that bivalirudin was superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial infarction undergoing percutaneous coronary intervention. Findings were first reported at last year's Transcatheter Cardiovascular Therapeutics, the annual scientific symposium of the Cardiovascular Research Foundation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2015 Category: Global & Universal Source Type: news

Trial of bivalirudin during angioplasty reports mixed results
(American College of Cardiology) Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints -- a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding -- as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 16, 2015 Category: Global & Universal Source Type: news

The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
SciClone to Promote Potential Hospital Market Leaders in China, ANGIOMAX® (bivalirudin) and CLEVIPREX® (clevidipine) PARSIPPANY, N.J. & FOSTER CITY, Calif.--(Healthcare Sales & Marketing Network)--The Medicines Company (MDCO), a global biopharma... Biopharmaceuticals, LicensingThe Medicines Company, SciClone Pharmaceuticals, ANGIOMAX, CLEVIPREX (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2014 Category: Pharmaceuticals Source Type: news

Medicines Co wins patent infringement suit against Mylan
(Reuters) - A U.S. court ruled Mylan Inc infringed the Medicines Co's patent on its blood-clot-inhibitor Angiomax, according to a court filing on Monday. (Source: Reuters: Health)
Source: Reuters: Health - October 28, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Bivalirudin vs Heparins With Bailout GP Iib/Iiia InhibitorsBivalirudin vs Heparins With Bailout GP Iib/Iiia Inhibitors
Find out more about the advantage of bivalirudin observed in comparison with heparins only with GPI used as bailout -- in patients with STEMI undergoing PCI. European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2014 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

TCT Hallway Buzz: The BRIGHT Trial
WASHINGTON (MedPage Today) -- The BRIGHT trial favored bivalirudin (Angiomax) over heparin in PCI, but was the heparin dose responsible? In this exclusive video, Rod H. Stables, MA, DM, discusses some caveats. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 16, 2014 Category: Journals (General) Source Type: news

Light From BRIGHT: More Fuel for Bivalirudin-Heparin DebateLight From BRIGHT: More Fuel for Bivalirudin-Heparin Debate
US cardiologists are finally getting a look at the Chinese BRIGHT trial, heralded as the first three-way randomization of bivalirudin, heparin, and heparin plus a GP IIb/IIIa inhibitor. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 15, 2014 Category: Cardiology Tags: Cardiology News Source Type: news

TCT: Bivalirudin Cuts Bleeding in PCI
WASHINGTON (MedPage Today) -- A prolonged infusion of bivalirudin (AngioMax) around percutaneous coronary intervention reduced bleeding compared with heparin, with or without glycoprotein IIb/IIIa inhibition, a Chinese trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 15, 2014 Category: Cardiology Source Type: news

New Revascularization Guidelines Trim Back Bivalirudin, DAPTNew Revascularization Guidelines Trim Back Bivalirudin, DAPT
New European guidelines for PCI and CABG in stable CAD, NSTEMI, and STEMI were unveiled last week with some key changes from previous documents. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 11, 2014 Category: Cardiology Tags: Cardiology News Source Type: news

Bivalirudin versus heparin in patients planned for coronary stenting
(Brigham and Women's Hospital) Researchers from Brigham and Women's Hospital conducted an analysis of all of the previous trials to date to better define both the benefits and risks of the competing anticoagulants. They found that, compared with heparin-based regimens, bivalirudin-based regimens increased the risk of heart attack and stent thrombosis. Bivalirudin-based regimens decreased the risk of bleeding, but by how much depended on whether other blood thinners were used more with heparin than with bivalirudin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 15, 2014 Category: Global & Universal Source Type: news

Consistency of Signals in Bivalirudin/Heparin Meta-Analysis Consistency of Signals in Bivalirudin/Heparin Meta-Analysis
Authors of a new meta-analysis of bivalirudin vs heparin trials of PCI patients say their findings provide a cool second look at a debate that reached a new boiling point in HEAT-PPCI. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news

Heparin in Stent Patients: New Love for an Old Friend (CME/CE)
(MedPage Today) -- Results of a meta-analysis of data from some 34,000 PCI patients suggest that Angiomax (bivalirudin) may not be the best choice for anticoagulation in stent patients, but an old, cheap drug -- heparin -- could be. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 14, 2014 Category: Geriatrics Source Type: news

PCI and ACS: Where Do Vorapaxar and Bivalirudin Fit In?PCI and ACS: Where Do Vorapaxar and Bivalirudin Fit In?
Drs. Pereira and Sandhu discuss contemporary therapy now that vorapaxar is approved. Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 30, 2014 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Choices, Choices: PCI Adjunctive PharmacotherapyChoices, Choices: PCI Adjunctive Pharmacotherapy
Drs. Mehran and Cuisset discuss key studies from EuroPCR and the role of bivalirudin in a post-EUROMAX, post-HEAT-PPCI world. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 10, 2014 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Heparin Beats Bivalirudin in Primary PCI (FREE)
By Larry Husten Edited by David G. Fairchild, MD, MPH, and André Sofair, MD, MPH Bivalirudin is associated with a higher rate of major adverse cardiac events than heparin in patients with myocardial infarction undergoing primary percutaneous coronary intervention, according to a Lancet study.Roughly 1800 patients undergoing primary … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 8, 2014 Category: Primary Care Source Type: news

Controversial Trial Finds No Benefit For Expensive Medicines Company Drug
Although there is broad consensus in the medical community that immediate stenting (primary PCI) is the best treatment for heart attack patients when it can be delivered promptly, there is no agreement about the best accompanying drug regimen, which usually entails a combination of antiplatelet and antithrombotic drugs. The role of one antithrombotic, bivalirudin (Angiomax, The Medicines Company) has been particularly uncertain because it is far more expensive than its alternative, unfractionated heparin. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 7, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news